A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2018
Price : $35 *
At a glance
- Drugs Tralokinumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors AstraZeneca
- 09 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 28 Jan 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 28 Jan 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.